Serine and 1-carbon metabolism are required for HIF-mediated protection against retinopathy of prematurity

Charandeep Singh,1 George Hoppe,1 Vincent Tran,1 Leah McCollum,1 Youstina Bolok,1 Weilin Song,1 Amit Sharma,1 Henri Brunengraber,2 and Jonathan E. Sears1,3

1Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA. 2Department of Nutrition, Case Western Reserve University, Cleveland, Ohio, USA. 3Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, Ohio, USA.

We determined which metabolic pathways are activated by hypoxia-inducible factor 1–mediated (HIF-1–mediated) protection against oxygen-induced retinopathy (OIR) in newborn mice, the experimental correlate to retinopathy of prematurity, a leading cause of infant blindness. HIF-1 coordinates the change from oxidative to glycolytic metabolism and mediates flux through serine and 1-carbon metabolism (1CM) in hypoxic and cancer cells. We used untargeted metabolite profiling in vivo to demonstrate that hypoxia mimesis activates serine/1CM. Both [13C6] glucose labeling of metabolites in ex vivo retinal explants as well as in vivo [13C3] serine labeling of metabolites followed in liver lysates strongly suggest that retinal serine is primarily derived from hepatic glycolytic carbon and not from retinal glycolytic carbon in newborn pups. In HIF-1α2lox/2lox albumin-Cre–knockout mice, reduced or near-0 levels of serine/glycine further demonstrate the hepatic origin of retinal serine. Furthermore, inhibition of 1CM by methotrexate blocked HIF-mediated protection against OIR. This demonstrated that 1CM participates in protection induced by HIF-1 stabilization. The urea cycle also dominated pathway enrichment analyses of plasma samples. The dependence of retinal serine on hepatic HIF-1 and the upregulation of the urea cycle emphasize the importance of the liver to remote protection of the retina.

Introduction

Retinopathy of prematurity (ROP) is the most common form of infant blindness worldwide, accounting for 150,000 blind children annually (1). Survival after premature birth requires oxygen supplementation that is paradoxically associated with toxicity to premature developing tissues, such as the lung alveoli, nephrons of the kidney, cerebral cortex, and retinal capillaries (2). The direct relationship of higher oxygen saturation to disease severity has placed the oxygen-sensitive transcription factor hypoxia-inducible factor (HIF) as a central mediator of retinovascular growth and hence protection against ROP because eyes that have retinovascular growth attenuation develop severe ROP (3–5). We have definitively demonstrated the safety and efficacy of HIF stabilization in the prevention of oxygen-induced retinopathy (OIR). This was achieved via inhibition of HIF-α catabolism through blockade of HIF prolylhydroxylase (HIF PHD), resulting in a protected phenotype for both retina and lung simultaneously by systemic HIF PHD inhibition (6–8).

HIF-1 mediates adaptive metabolic responses of cells to hypoxia by increasing flux through glycolysis and decreasing entry of glycolytic carbon into the tricarboxylic acid (TCA) cycle (9). This occurs through upregulation of the PDK1 gene encoding pyruvate dehydrogenase kinase, which inactivates pyruvate dehydrogenase (10). Reduced flux through oxidative phosphorylation by HIF-1 decreases reactive oxygen species production (10). HIF also increases serine synthesis and metabolism by upregulating phosphoserine aminotransferase, phosphoglycerate dehydrogenase (PHGDH), and mitochondrial serine hydroxymethyltransferase 2 (SHMT2), contributing to increased mitochondrial NADPH production (11–14). HIF-1 stabilization induces serine synthesis from the intermediary metabolite 3-hydroxypropyruvate, which is found in retinas from hyperoxic animals cycled through the OIR model (15). The conversion of 3-hydroxypropyruvate to 3-phosphoglycerate, the precursor to serine, is initiated by glyoxylate reductase/hydroxypropyruvate reductase, also induced by HIF-1 (15, 16).
Hypoxia mimesis can be created pharmaceutically through inhibition of HIF PHD (17). These $\alpha$-ketoglutarate–dependent ($\alpha$-KG–dependent) enzymes are part of the superfamily of dioxygenases. PHDs split molecular dioxygen to (a) hydroxylate regulatory proline residues on target proteins and (b) oxidize $\alpha$-KG to succinate and CO$_2$ (18, 19). There are multiple targets of PHDs; perhaps the most notable of these are the HIF transcription factors (19–21). Inhibition of dioxygenases even in hyperoxia can be induced using small-molecule carbonyl glycines that are antagonistic, competitive $\alpha$-KG analogs (22, 23). The regulation of dioxygenase activity by $\alpha$-KG and oxygen renders these enzymes responsive to both oxygen tension and metabolic intermediates (24).

Transcriptional and knockout studies of animals treated with PHD inhibition have determined a unique liver-eye and liver-heart axis that directs “remote” protection against OIR and cardiac ischemia, respectively (25, 26). Here we used untargeted metabolite profiling to demonstrate that (a) retinal serine/glycine concentrations and (b) activation of retinal serine/1-carbon metabolism (1CM) are hepatic HIF-1 dependent. This supports a metabolic phenotype of mice protected by pharmacologic HIF stabilization against oxygen toxicity. These results demonstrate the importance of 1CM to HIF-1–mediated protection against OIR and further implicate the liver as a mediator of remote protection.

**Results**

To determine which metabolic pathways are globally increased by HIF PHD inhibition in the liver and retina, we treated newborn mouse pups exposed to hyperoxia with either sham intraperitoneal (i.p.) injection of phosphate-buffered saline (PBS) or Roxadustat (RXD), an HIF PHD inhibitor (27). We then analyzed the metabolites in the plasma and retina from pups using untargeted liquid chromatography tandem–mass spectrometry (LC-MS/MS) analysis. Figure 1, A–D, shows the principal component analysis (PCA) of positive and negative modes from plasma and retina in hyperoxia and hyperoxia plus HIF stabilization. Untargeted metabolite profiling was used for an unbiased measurement of the polar metabolites present in the plasma and retina samples. Every sample was measured 2 times, once in positive mode and then in negative mode, using the ZIC-HILIC-ddMS2 method (zwitterionic-hydrophilic interaction liquid chromatography–data-dependent mass spectrometry). Data were analyzed using XCMS Online tool (28), and unsupervised PCA clearly indicated differences in metabolic features present in the plasma or retina harvested from controls and RXD-treated mice (Figure 1, A–D).

XCMS cloud plot analysis of plasma samples revealed changes in 613 (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.129398DS1) and 398 (Supplemental Figure 1B) metabolic features with $P$ value less than or equal to 0.01 and fold change at least 1.5 in the positive and negative modes, respectively, when comparing hyperoxic control and RXD-treated hyperoxic mouse plasma samples. In contrast, retina cloud plot analysis showed 82 (Supplemental Figure 1C) and 23 (Supplemental Figure 1D) metabolic features with $P$ value less than or equal to 0.01 and fold change at least 1.5, in positive and negative modes, respectively.

To define the most important biochemical pathways that produced these metabolic differences, we performed system-level analysis using XCMS Online systems biology tool. Systems biology analyses of the metabolomics data in XCMS Online are based on mummichog analysis of the metabolite features (29). The conventional approach to metabolomics analysis is to first identify metabolites based on the exact mass of the compound and then to map them onto a metabolic network of the organism under investigation. However, mummichog analysis is a recursive approach where metabolite feature identification and mapping onto metabolic network are considered correlated events. All the features differing between 2 conditions are mapped onto multiple pathways specific to an organism of interest (in our case the mouse), and the pathways with the best fit are displayed as outputs (Figure 2, A–D, and Supplemental Tables 1–4). Of those, branches of serine/1CM and urea cycle populated the pathway enrichment graphs. For example, pathways such as glycine-betaine, glycine, glutathione, creatine, folate, serine, and purine all need serine as a precursor. Similarly, citrulline, arginine, nitric oxide, and glutamine all are interlinked by the urea cycle. This analysis definitively demonstrated induction of serine/1CM and urea pathways by RXD.

We next analyzed data manually and looked at metabolites within the serine and urea pathways (see Supplemental Figures 2 and 3 and Figure 2E, selected metabolites). MS2 peak areas of the compounds confirmed by MS2 library matches and manual analysis were plotted for all 3 conditions, i.e., normoxia, hyperoxia, and hyperoxia plus RXD (Figure 2E). We found 50% or higher increased levels of plasma serine, glycine, hypotaurine, cystathionine, methionine, LysoPC18:2, and taurine from RXD-treated animals.
in hyperoxia compared with control hyperoxic animals (Figure 2E, selected metabolites; Supplemental Figure 2, plasma; and Supplemental Figure 3, retina). In addition, metabolites of the urea cycle were increased under HIF stabilization. For example, N-acetylglutamate increased 4-fold in plasma, while ornithine, citrulline, arginine, aspartate, and glutamine were at least 50% increased in the RXD-treated mouse plasma, as demonstrated in Supplemental Figure 2. N-acetylglutamate is an allosteric activator of carbamoyl phosphate synthetase 1, the first enzyme in the urea cycle pathway.

[13C3] serine atom transitions in 1CM are summarized in Figure 3A. To test the relevance of 1CM to protection against OIR, we treated mouse pups with methotrexate (MTX) to inhibit dihydrofolate reductase, in the first (hyperoxic) phase of OIR from postnatal day 6 (P6) to P11, to prevent use of carbon extracted from serine. MTX-treated animals had a decreased protective response to HIF stabilization when comparing control-injected PBS (Figure 3D) to RXD (Figure 3E) or RXD plus MTX (Figure 3F). In animals in which serine use was inhibited by MTX, there was a 55% reduction in protection manifested by an increase in vaso-obliteration, as quantified in Figure 3B. MTX had no effect on pathological angiogenesis or neovascularization (Figure 3F, quantified in Figure 3C), presumably because it was administered only in phase 1 (hyperoxia). In addition, MTX did not increase vaso-obliteration in PBS controls, demonstrating that it blocked protection by RXD but was not additive to hyperoxia likely because hyperoxia had already downregulated 1CM. The LD50 established for MTX is around 94 mg/kg of mice weight (30), which is around 470 times higher than the dose used in our experiment. To test whether MTX inhibits serine to glycine conversion at this low dose we used in our experiments, we injected [13C3] serine into the...
Figure 2. Pathway cloud plot depicting various metabolic pathways affected by RXD. All the data in this figure are from mice dissected on postnatal day 10 (A–D), and bar graph of annotated metabolites (E) shows that PHI targets the serine/1C pathway. Metabolite features were analyzed through a pathway prediction algorithm in XCMS Online tool, and statistically significant pathways with P value less than 0.05 are depicted in these plots. Data were projected onto a mouse-specific database available on XCMS. Please also see pathway tables in Supplemental Tables 1–4. (A) Positive mode plasma data. (B) Negative mode plasma data. (C) Positive mode retina data. (D) Negative mode retina data. Serine/1CM metabolic pathways are highlighted in orange. Targeted data analysis was performed on a few metabolites from the serine/1C pathway. Identities of metabolites were confirmed using MS1 exact mass and MS2 fragmentation pattern. (E) Selected plasma metabolites (n = 6 for each condition) and retina metabolites (n = 4 for each condition). P values are shown below the x axis.
pups and measured serine to glycine conversion. Serine to glycine conversion was indeed decreased in liver and retina in the MTX-treated mice pups (Supplemental Figure 4, A–L).

To test whether the liver increased serine metabolism under HIF stabilization, we performed in vivo dynamic labeling experiments on hyperoxic PBS- and RXD-treated mouse pups by injecting $[13C_3]$ serine injected subcutaneously was followed in liver extracts, demonstrating conversion to M2 glycine, M2 hypotaurine, and M2 taurine, all metabolites of 1CM. (H) The change in retinal serine and glycine using a hepatic-specific HIF stabilizer in wild-type (WT) versus HIF-1α2lox/2lox albumin-Cre–knockout (HIF-1α–KO) mice. (n = 6 animals in each group.) (I) Serum serine and glycine levels in the WT versus HIF-1α2lox/2lox, DMOG-injected mouse metabolite extracts. Metabolites were extracted from the serum at different time points after DMOG i.p. injections. * 2-tailed t test P values less than 0.05.
serine subcutaneously and measured downstream metabolites of 1CM in liver (Figure 3G). Liver extracts demonstrate that RXD increased hepatic serine use, demonstrated by increased ratios of M2 glycine/M3 serine, M2 taurine/M3 serine, and M2 hypotaurine/M3 serine (Figure 3G) 1 hour after subcutaneous injection of serine tracer.

We next determined whether metabolites of retinal 1CM are dependent on hepatic HIF-1 stabilization by measuring retinal serine/glycine concentrations in the hepatic HIF-1–knockout mouse (conditional Cre-lox HIF-1α [HIF-1αΔin2lox/2lox albumin-Cre] hepatic knockout) (HIF-1–KO, see Supplemental Figure 5 for tissue specificity) with and without HIF stabilization. To ensure that we were analyzing only the hepatic contribution to increases in retinal serine, we used dimethyloxalylglycine (DMOG), a widely studied α-KG antagonist and nonselective inhibitor of HIF PHD. We have definitively demonstrated that DMOG can protect only the wild-type mouse but not the hepatic HIF-1–KO, demonstrating the HIF-1 dependence of the liver to eye protection using DMOG (25). The liver selectivity of DMOG is likely a consequence of DMOG’s instability and inability to survive intact after a first pass through the liver. In cell culture, DMOG is rapidly hydrolyzed to either n-oxalylglycine or methyl oxalylglycine (31). To prove that DMOG does not enter plasma, we used LC-MS/MS to analyze plasma from animals treated with either DMOG or RXD injected i.p. Supplemental Figure 6A, top, shows the DMOG standard compared to middle and lower in Supplemental Figure 6A, which demonstrates that DMOG does not survive the first pass through the liver because there was no peak with exact mass and retention time corresponding to that of the authentic DMOG standard. In contrast, Supplemental Figure 6B shows RXD standard (top) and peak in plasma and retina with same m/z, retention time, and MS2 spectrum in the plasma (middle) and retina (lower) of the mice injected with RXD. Supplemental Figure 6C shows preservation of RXD in plasma and retina measured as area under the curve, further confirmed by MS2 analysis (Supplemental Figure 6) in plasma and retina, which reveals identical fragmentation patterns. DMOG, unlike RXD, targets only the liver and cannot reach the retina. These data support the observation that systemic HIF-1 stabilization by DMOG protects only the wild-type mouse from oxygen toxicity but does not protect the hepatic HIF-1–KO (25). We therefore next used the hepatic HIF-1–KO mice treated with DMOG to test whether metabolites of 1CM were reduced in the hepatic HIF-1–KO. Measurements of retinal serine and glycine in the hepatic HIF-1–KO mice (Figure 3H) showed that hepatic HIF-1 modulated retinal serine and glycine concentrations. Both retinal serine and glycine were decreased in the HIF-1–KO compared with WT mice in the same hyperoxic conditions with HIF stabilization by DMOG. We also measured serine levels in serum samples from DMOG-injected WT and HIF-1–KO time course. Serine levels were same at the start of the time course, 0 minutes after DMOG injection. The WT demonstrates higher levels of serum serine than the KO at 24 hours after injection with DMOG, with a t-test P value of 0.01 (Figure 3I).

Discussion

Our hepatic HIF-1–KO mouse studies clearly demonstrate that retinal serine/glycine depends on liver HIF-1. We next measured the glycolytic fluxes in retina by stable isotope-based metabolomics. The atom transitions of [13C6] glucose are provided in Figure 4A. HIF stabilization induced a very small (less than 10%) increase in the glycolytic fluxes in retinal explants, measured as M3 isotopolog of lactate, in RXD-treated versus untreated retinal explants (Figure 4, B and C). There was a very high baseline rate of glucose to lactate conversion by retina found to be 332 nmol/h/mg (wet-weight basis). This value is in the range of that previously reported (32, 33). Lactate measurements were necessary to confirm that glucose was oxidized in these experiments. In contrast, there was no enrichment of either M3 serine or M2 glycine (Figure 4, D and E), indicating that retina does not use glycolytic carbon to synthesize serine; if so, serine would be labeled M3 and derived from M3 3-phosphoglycerate. Lactate M3 labeling is clear proof of M3 labeling of 3-phosphoglycerate, yet there was no shuttling of 3-phosphoglycerate to the serine pathway in retinal explants with or without HIF stabilization. The incubation also included nitrogenous substrate (glutamine) that would have allowed synthesis of labeled amino acids from glucose. The small amount of M1 serine may imply anaplerosis from M3 pyruvate and production of retinal serine by decarboxylation of malate, although this putative process would have likely yielded other isotopologs (Figure 4D).

**Discussion**

Our data demonstrate hepatic HIF-1–dependent regulation of the urea cycle and serine/1CM in a proangiogenic strategy to protect retinal blood vessels. These findings suggest a metabolic mechanism to explain how remote protection induced by hepatic HIF PHD inhibition could protect peripheral capillary beds, inasmuch as both pathways rely on hepatic metabolism. Our approach of using analysis of metabolic
features derived from in vivo models with and without small molecules that stabilize HIF demonstrates a different perspective of Systems Pharmacology, which ordinarily relies on transcriptional analysis. Our previous study of this topic does reveal specific upregulation of SHMT2, methylene tetrahydrofolate dehydrogenase 2, and MTHDF1L (MTHDF-like), indicating the HIF-1 induction of mitochondrial 1CM that produces glycine and ultimately formate for regeneration of serine in the cytosol (Gene Expression Omnibus GSE74170; ref. 16).

Although our experiments clearly demonstrate that whole retinal explants do not synthesize serine from glycolytic carbon, endothelial cells in culture, such as primary hepatic endothelial cells and human umbilical vein endothelial cells, produce serine (34). Tamoxifen-induced KO of PHGDH in endothelial cells systemically also induces decreased retinovascular growth (34). Retinal endothelial cells also synthesize serine if they are both HIF stabilized and given 3-hydroxypyruvate simultaneously (15). However, our in vivo experiments strongly suggest that the liver is primarily responsible for serine/glycine synthesis, at least in the newborn mouse. This correlates to experiments in sheep fetuses, where the flux of serine is measured at 2700 μmol/h/kg. The sheep fetal liver is primarily responsible for serine production from glycine taken up from the placenta (35).

Loss of function of PHGDH, a rate-limiting enzyme for serine synthesis, is associated with macular telangiectasia (MacTel; ref. 36). Yet, the average age of onset of MacTel is 50 to 60 years (37), suggesting that if 1CM is relevant to disease pathogenesis, it is associated with senescence or perhaps compensated by systemic sources of serine/glycine. Our hepatic HIF-1–KO model was not completely devoid of retinal serine, but retinal glycine levels were near 0.

A natural question is whether serine supplementation can protect against OIR. We have tried high doses of i.p. serine and found no effect (data not shown). We considered that serine was catabolized too rapidly to confer protection or that protection requires upregulation of a specific transporter, such as mitochondrial sideroflexin 1, a multipass mitochondrial membrane protein (38). In addition, 1CM may not respond solely to substrate concentrations but require upregulation of HIF-1–dependent enzymes within the cycle.

Figure 4. Ex vivo [13C6] glucose labeling of retina and in vivo [13C3] serine labeling of liver demonstrates that retinal serine is derived from liver. Retinal explants were incubated in Krebs-Ringer buffer (KRB) medium containing 5 mM [13C6] glucose and 1 mM [13C] glutamine. As expected, a very high rate of [13C6] glucose to [13C3] lactate was observed, whereas no comparable 13C carbon enrichment was seen in serine or glycine, indicating that glycolytic flux in retina is not responsible for serine or glycine formation. (A) Schematic showing expected labeling from the first-round carbon flow from glucose to glycolytic and TCA cycle intermediates when labeled with [13C6] glucose. (B) Media labeling of the lactate by retina sampled 5 hours after incubation with [13C6] glucose. (C) Lactate production rate was not significantly changed between PBS controls and RXD-treated retina explants. (D) Intracellular labeling of serine in retina shows that retina did not synthesize serine from glucose because M0 was the dominant metabolite sampled 5 hours after incubation with [13C6] glucose. (E) Intracellular labeling of glycine, like serine, was M0 and hence not derived from glucose sampled 5 hours after incubation with [13C6] glucose.
HIF-1 stabilization at the beginning of the OIR cycle induced ureagenesis. In contrast, without HIF stabilization, ureagenesis is upregulated at the end of the OIR cycle (39). Pathological angiogenesis, termed neovascularization, occurs by way of a 2-step hypothesis (40–42). Phase 1 is the initiating event created by hypoxia that leads to vascular obliteration and retinovascular growth attenuation. Neovascularization, associated with phase 2 at the end of the OIR cycle, is a reaction to oxygen-induced ischemia that creates severely hypoxic retina as mice are returned to room air after hyperoxia, or in the case of infants, as oxygen supplementation is withdrawn as these severely premature infants survive. It is interesting that an increase in the urea cycle pathway, normally seen in the whole-eye metabolome of phase 2 OIR and in the vitreous cavity of patients with diabetes (39), was shifted to phase 1 by HIF stabilization. If this represents part of vasoproliferation or vascular repair, it is beneficial to shift this response to phase 1 using hypoxia mimesis (HIF stabilization) because this is exactly when a pro-angiogenic response would be protective.

In conclusion, untargeted metabolite profiling in combination with pharmaceutical hypoxic preconditioning in vivo demonstrates that (a) systemic HIF stabilization requires ICM to protect against OIR and (b) retinal serine/glycine concentrations are hepatic HIF-1 dependent.

**Methods**

Reagents. LC-MS–grade methanol (HiPerSolv Chromanorm; BDH VWR International) and chloroform (LiChrosolv; MilliporeSigma) were used for all the metabolite extractions. Stable isotopes were purchased from Cambridge Isotope Laboratories and were at least 99% pure. MTX was purchased from Cayman Chemicals. N-methyl-(N-(trimethylsilyl))trifluoroacetamide (MSTFA) was purchased from Macherey-Nagel and MSTFA with 1% trimethylchlorosilane (TMCS) was purchased from Thermo Fisher Scientific. All the chemicals and metabolite standards were purchased from MilliporeSigma. KRB medium was prepared fresh as per recipe provided in Du, Linton, and Hurley (43). Hanks' balanced salt solution (HBSS) and PBS were purchased from Cleveland Clinic Media Lab.

Ex vivo retinal explant and in vivo whole-mouse isotopic labeling. For isotopic labeling experiments, retinas were dissected out while keeping eyes in ice-cold KRB medium containing 15 mM glucose. Samples were then washed with PBS and centrifuged at 300 g at room temperature for 2 minutes to remove the PBS. The retina samples were then carefully transferred to KRB medium containing 5 mM $^{13}$C$_6$ glucose, 1 mM $^{12}$C glutamine, and 10% dialyzed FBS. Media samples were obtained at 0, 5, 30, 120, 180, and 300 minutes; retinal explants were harvested at 300 minutes and metabolites extracted as described below. To perform the in vivo labeling of whole mice, pups were separated on P10 of the OIR model from their mother 6 hours after RXD injection and then injected with 80 μL of 10 mg/mL subcutaneous injections of $^{13}$C$_3$ serine; mouse tissues were taken out at 1 hour after serine injections and metabolites extracted as described below.

**MTX isotopic labeling experiment.** C57BL/6J WT mice were kept in hyperoxia from P10 to P12. RXD was administered on P10 and P12, and MTX 0.2 μg/mg of body weight was injected every day. On P12, mice were injected the last dose of MTX and separated from nursing dam for 1 hour. Thirty minutes after MTX injections, 80 μL of 6 mg/mL $^{15}$C$_3$ serine was injected subcutaneously, and mice were placed back in the hyperoxic chamber. At the end of the experiment, mice were anesthetized with ketamine/xylazine mix and euthanized to dissect livers. Twenty milligrams of liver was used to extract metabolites. Samples were processed as described later in the text, and 300 μL of upper phase from metabolite extraction was dried per sample. Metabolites were measured with a gas chromatography–mass spectrometry (GC-MS) scan method very similar to as described later in the next section and were measured on ZORBAX DB-5ms +10m DuraGuard Capillary Column (Agilent) and with split 1:10 injection.

Collection of tissues from mice and metabolite extraction. To extract the blood samples, mice were anesthetized with ketamine/xylazine mix, and then blood was extracted from the heart of the animal with a 27.5-gauge needle fixed onto a 1-cc heparinized syringe. The extract was added to 1.5-mL tubes containing 1.5 μL of heparin 10,000 USP units/mL (Hospira) and stored on ice until further use. Eyes were enucleated and retinas were dissected in cold HBSS under the microscope. Tubes containing retina were immediately frozen in liquid nitrogen. Liver was also quickly dissected and snap-frozen in liquid nitrogen as well. Plasma was obtained from blood samples by centrifuging samples at 1100 g at 4°C for 20 minutes.

Metabolites from retina (2 retinas were combined per tube) were extracted using methanol/chloroform/water phase separation. Briefly, 400 μL of –20°C cold methanol was added to 400 μL of 4°C water. Samples were then briefly sonicated and 400 μL of –20°C cold chloroform was added. Samples were then vortexed on a thermomixer (Thermomixer C; Eppendorf) at 4°C for 20 minutes at 1400 rpm and were then
centrifuged at 15,000 g at 4°C for 5 minutes, following which the upper phase containing polar metabolites was separated into fresh vials and injected directly into the LC-MS or dried for the GC-MS analysis.

Metabolites from plasma were extracted by adding 20 μL of plasma to 500 μL of 50% cold acetonitrile. Samples were centrifuged at 15,000 g for 10 minutes, and 400 μL supernatant was carefully removed into fresh tubes without disturbing the cell pellet. Supernatants were either injected directly into the LC-MS or 300 μL dried for the GC-MS analysis.

Metabolites from serum were extracted by adding 10 μL of serum using the same protocol as described above for plasma samples. Three hundred microliters of supernatant was dried for the GC-MS analysis. Metabolites were measured with a GC-MS scan method very similar to as described later in the next section and were measured on ZORBAX DB-5ms +10m DuraGuard Capillary Column and with split 1:10 injection.

Metabolites from media in which retinal explants were cultured were extracted by diluting 15 μL of media with 15 μL of –20°C cold methanol. Media samples were centrifuged at 15,000 g at 4°C for 5 minutes, following which 20 μL of sample was dried for derivatization and GC-MS measurement.

Metabolites from liver were extracted using methanol/chloroform/water protocol as described above but with slight differences. Briefly, 20 mg of liver sample was weighted per tube, crushed with disposable pestle, and added to 50 μL of 50% methanol (–20°C cold). Samples were sonicated on ice to break open the cells, and additional methanol, water, and chloroform were added to get to a final mixture with 400 μL of each solvent. Samples were then vortexed on a thermomixer at 1400 rpm at 4°C for 20 minutes, followed by centrifugation at 15,000 g at 4°C for 5 minutes. Supernatant was removed into a fresh 1.5-mL tube and diluted 1:1 with 50% of –20°C methanol. The diluted sample, 360 μL volume, was dried and derivatized for GC-MS measurement.

For GC-MS measurements, samples were dried under vacuum at –4°C with subsequent drying at 30°C for 10 minutes to ensure no trace of moisture was present in the samples. Samples were then derivatized using a 2-step protocol. First, the sample was derivatized with 25 μL of 40 mg/mL of MTX in pyridine at 45°C for 30 minutes. We followed up with an additional derivatization step by adding 75 μL of MSTFA (MSTFA+ 1% TMCS was used in the liver stable isotope tracer experiment) at 45°C for 30 minutes. Samples were packed in airtight GC-MS vials, and 1 μL of the sample was injected into the mass spectrometer. GC-MS was used in either electron ionization (EI) or chemical ionization (CI) with methane as a reagent gas.

**LC-MS/MS measurement of polar metabolites.** Untargeted metabolomics was performed on the UPLC (Vanquish, Thermo Fisher Scientific) connected to Q-exactive HF mass spectrometer (Thermo Fisher Scientific). Chromatographic separation was performed on SeQuant ZIC-HILIC column with dimensions 150 × 2.1 mm, 3.5 μm, 100 Å (Merck), attached to a precolumn SeQuant ZIC-HILIC with dimensions 20 × 2.1 mm, 3.5 μm, 100 Å (Merck). The LC method used for separation of metabolites using the ZIC-HILIC column was adapted from Singh et al. (44). Briefly, gradient of solvent A (0.1% formic acid in water) and solvent B (0.08% formic acid in acetonitrile) was ramped from 80% B to 35% B in 23 minutes, followed by a wash step with 5% B from 25 to 30 minutes and then re-equilibration with 80% B from 25 to 30 minutes. Column oven was set to 20°C, and a constant flow of solvents was set to 150 μL/min. Samples were kept on 4°C autosampler throughout the measurements, and 5 μL (retina) or 10 μL (plasma) of sample was injected. Heated electrospray ionization (ESI) source settings used for the mass spectrometer were spray voltage 3500 (positive mode) and 2500 (negative mode), capillary temperature 250°C, sheath gas 40, and auxiliary gas 10. Mass spectrometer method used was data-dependent MS2, where a full scan (survey) was recorded followed by MS2 scans for the top 5 peaks seen in the survey full scan. MS1 parameters were MS1 m/z window set from 70 to 1050 mass cutoff, resolution of 120,000, automatic gain control of 3 × 10⁶ and maximum injection time of 100 ms. MS2 values were recorded for the top 5 peaks after every MS1 scan, with 17,000 mass resolution, an automated gain control of 10⁶, maximum injection time of 50 ms, and precursor ion isolation width of 2 m/z. A normalized collision energy of 40% was applied, a dynamic exclusion of 10 seconds was applied to exclude the redundant MS2 scans, isotope exclusion was applied, and underfill ratio of 1% was applied.

DMOG pharmacokinetics measurements were performed with a longer gradient method. The same machine, columns, and solvents were used, except that the LC method was as follows: 80% B to 20% B followed by washing with 5% B from 31 to 39 minutes and final re-equilibration step with 80% B from 40 to 50 minutes. This LC method was run with a full-scan mass spectrometry method with positive-negative switching. The full scans were recorded with a mass range of 70 to 1050 m/z at a mass resolution of 60,000, automatic gain control set to 3 × 10⁶, and maximum injection time of 200 ms. This method was adapted from Singh et al. (44).
LC-MS data analysis. LC-MS data from ddMS2 measurement were converted to mzML format using compound discoverer (version 2.1, Thermo Fisher Scientific) and analyzed using XCMS Online tool (28). The metabolites were mapped onto the mouse database available on XCMS (28). Data were also analyzed with MSdial tool to confirm some of the metabolite annotations, using the library provided with the MSdial software (45, 46).

GC-MS measurement of metabolites. Lactate labeling from the media of retinal explants, and serine and glycine labeling from retinal intracellular extracts from explant cultures, were measured on GC (6890N, Agilent Technologies) coupled to EI mass selective detector (5973 MSD, Agilent Technologies) mass spectrometer using the method described in Singh et al. (15).

In vivo liver metabolite labeling samples were measured on GC (7890B, Agilent Technologies) coupled to EI/CI (extractor EI source) mass selective detector (5977B MSD, Agilent Technologies) mass spectrometer. CI ion source was set to a constant 70 eV potential. Methane was used as a reagent gas, and CI was performed in positive mode ionization. CI source was held at a constant temperature of 300°C and quadrupole set at a constant temperature of 150°C. Transfer line was held at 290°C and front-inlet temperature was 250°C. GC column oven was set at 60°C starting temperature and was held for 1 minute. Temperature was ramped at a rate of 10°C/min from 60°C to 325°C with a constant flow of helium gas at 1.1 mL/min. Agilent Technologies HP-5ms inert column 30 m × 250 μm × 0.25 μm was used for separation of derivatized metabolites.

All the data were analyzed using metabolite detector (47), MSD Chemstation (Agilent Technologies), and MassHunter Workstation Unknowns Analysis (Agilent Technologies) software. NIST17 (NIH) and Fiehn 2013 (Agilent Technologies) libraries were used for GC-MS data analysis.

Isocor software version 1.0 was used to derive mass isotopolog distributions for metabolites (48).

OIR model, RXD and MTX treatments, and retinal vasculature analysis. WT C57BL/6J mice were supplied by the Jackson Laboratory. OIR model was based on the previously described procedure developed by Smith (49) and was described in detail elsewhere (50–52). Briefly, newborn pups with their nursing dam were subjected to 75% oxygen in the Biospherix animal hyperoxia system (Biospherix Ltd.) from P7 to P12. RXD (10 μg/g BW, Adooq) was injected i.p. at P6, P8, and P10, and MTX (0.2 μg/g BW, Cayman Chemical) was given i.p. daily from P6 to P11. At P17 mouse retinas were isolated, fixed, and stained with isolectin GS-IB 4 Alexa 568 Conjugate (Life Technologies) as previously described (25). Oxygen-induced vascular pathology, i.e., vaso-obliteration and neovascularization, was automatically quantified using deep learning segmentation software available at a free, public, open-source repository (53). PCR to confirm tissue specificity of the HIF-1 KO was performed as described in Hoppe et al. (8).

Availability of data and material. The untargeted metabolomics data have been submitted to public repository Metabolights and study ID is MTBLS856.

Statistics. Statistical analysis for both GC and LC data were performed in R version 3.4.0 2017-04-21 (54) and GraphPad Prism 7 for most of the data, except for XCMS-analyzed data. A P value of less than 0.05 was considered statistically significant. All error values are ±SEM.

Study approval. All experimental procedures involving live animals were conducted in accordance with the guidelines of the NIH’s Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011) and approved by the Cleveland Clinic institutional animal care and use committee (IACUC, protocol 2016-1677). All animal experiments conformed to the rules and regulations of the Association of Research in Vision and Ophthalmology.

Author contributions
CS, GH, HB, and JES designed experiments. CS and GH performed experiments. LM and YB performed OIR model experiments. LM, YB, and WS performed retinal flat mounts. LM and YB were responsible for PCR. VT and AS performed sample processing for metabolomics analyses. CS, GH, HB, and JES interpreted the data. CS and JES wrote the paper. GH and HB edited the paper.

Acknowledgments
This study was supported by the National Eye Institute (R01 EY024972 and P30 EY025585); The Hartwell Foundation Biomedical Research Fellowship (HWF06092015); and Research to Prevent Blindness Physician Scientist (RPB 1801). We appreciate the use of the LCMS/MS, supported by the Cleveland Clinic metabolomics core, Belinda Willard and Maryam Goudarzi.


